Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction.

ABSTRACT: AIMS:The effects of vericiguat vs. placebo on high-sensitivity C-reactive protein (hsCRP) and serum uric acid (SUA) were assessed in patients with heart failure with reduced ejection fraction (HFrEF) in the Phase?2 SOCRATES-REDUCED study (NCT01951625). METHODS AND RESULTS:Changes from baseline hsCRP and SUA values at 12?weeks with placebo and vericiguat (1.25?mg, 2.5?mg, 5.0 mg and 10.0 mg, respectively) were assessed. The probability of achieving an hsCRP value of ?3.0 mg/L or SUA value of <7.0 mg/dL at week?12 was tested. Median baseline hsCRP and SUA levels were 3.68?mg/L [interquartile range (IQR) 1.41-8.41; n?= 335] and 7.80?mg/dL (IQR 6.40-9.33; n = 348), respectively. Baseline-adjusted mean percentage changes in hsCRP were 0.2%, -19.5%, -24.3%, -25.7% and -31.9% in the placebo and vericiguat 1.25?mg, 2.5 mg, 5.0 mg and 10.0 mg groups, respectively; significance vs. placebo was observed in the vericiguat 10.0 mg group (P = 0.035). Baseline-adjusted mean percentage changes in SUA were 5.0%, -1.3%, -1.1%, -3.5% and -5.3% in the placebo, and vericiguat 1.25?mg, 2.5 mg, 5.0 mg and 10.0 mg groups, respectively; significance vs. placebo was observed in the 5.0 mg and 10.0 mg groups (P = 0.0202 and P = 0.004, respectively). Estimated probability for an end-of-treatment hsCRP value of ?3.0 mg/L and SUA value of <7.0 mg/dL was higher with vericiguat compared with placebo. The effect was dose-dependent, with the greatest effect observed in the 10.0 mg group. CONCLUSIONS:Vericiguat treatment for 12?weeks was associated with reductions in hsCRP and SUA, and a higher likelihood of achieving an hsCRP value of ?3.0 mg/L and SUA value of <7.0 mg/dL.

SUBMITTER: Kramer F 

PROVIDER: S-EPMC7687153 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature